UroGen Pharma Ltd. Accumulated Other Comprehensive Income
UroGen Pharma Ltd. (URGN) had Accumulated Other Comprehensive Income of -$2.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-05
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$2.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $8.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $19.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $23.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$2.00K 10-Q · filed 2026-08-05 |
| 2026-03-31 | $8.00K 10-Q · filed 2026-05-06 |
| 2025-12-31 | $19.00K 10-Q · filed 2026-08-05 |
| 2025-09-30 | $23.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $6.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $14.00K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $56.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $236.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | -$31.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | -$37.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $12.00K 10-K · filed 2025-03-10 |
| 2023-09-30 | -$134.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | -$154.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$45.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$107.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | -$155.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$56.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$69.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$25.00K 10-K · filed 2023-03-24 |
| 2021-09-30 | $4.00K 10-Q · filed 2021-11-15 |
| 2021-06-30 | $45.00K 10-Q · filed 2021-08-04 |
| 2021-03-31 | $143.00K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $271.00K 10-K · filed 2022-03-21 |
| 2020-09-30 | $492.00K 10-Q · filed 2020-11-09 |
| 2020-06-30 | $760.00K 10-Q · filed 2020-08-10 |
| 2020-03-31 | $311.00K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $276.00K 10-K · filed 2021-03-18 |
| 2019-09-30 | $303.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $281.00K 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |